Alarming Cancer Medication Defects in Sub-Saharan Africa Exposed

Strategic Insights -

A recent study published in The Lancet Global Health has revealed alarming statistics about cancer medication defects in sub-Saharan Africa. Researchers from the University of Notre Dame collected dosage information from a dozen hospitals and 25 pharmacies across Ethiopia, Kenya, Malawi, and Cameroon, testing 251 cancer drugs. The study found that 17% of cancer medications were defective, with some having as little as 28% or as much as 120% of the required active ingredient levels.

Key Takeaways:

  • 1 in 6 cancer medications in sub-Saharan Africa is defective, with 17% of tested drugs found to have incorrect active ingredient levels.
  • Researchers collected dosage information from 12 hospitals and 25 pharmacies across 4 countries, testing 251 cancer drugs.
  • The study found that barely a quarter of substandard products were identified through visual inspection, while laboratory testing identified the rest.
  • Dr. Marya Lieberman, lead author of the study, emphasized the importance of accurate dosage levels, stating that "if the patient's dose is too small, the cancer can survive and spread to other locations."
  • The researchers highlighted weak drug regulations, poor manufacturing standards, and unsafe storage and shipping conditions as contributing to the issue.
  • Similar numbers of substandard antibiotics, antimalarial, and tuberculosis drugs have been reported in the past, but this is the first time such a study has found high levels of falsified or defective anticancer drugs in circulation.
  • The World Health Organisation (WHO) has expressed concern and is working with the affected countries to address the issue.

Statistics:

  • 17% of cancer medications (1 in 6) were found to be defective in sub-Saharan Africa.
  • 251 cancer drugs were tested across several brands from both public hospitals and private markets.
  • Visual inspection only caught 1 out of 10 bad medicines.
  • The safe range for active ingredient levels is between 90% and 110% of what's written on the label.
  • Some medicines had as little as 28% and as much as 120% of the required active ingredient levels.

Sources:

  • University of Notre Dame researchers, published in The Lancet Global Health.
  • World Health Organisation (WHO) statement.
  • Study referenced in The Guardian.